Infliximab is a tumor necrosis factor-alpha inhibitor

Uses: IBD, psoriasis, RA, infammatory spondyloarthropahty.

Therapeutic latency in psoriasis is 3.5 weeks

AE: Headache, diarrhea, nausea, abdominal pain, elevated transaminases, elevated ANA, ds-DNA titers, abscess formation especially in Crohn's disease, URTI, and infusion reactions. Risk of malignancy, myelosuppression, opportunistic infections with hepatitis-B, TB, CIDP.

Treatment regimen:

• Infusion 5 mg/kg at 0, 2, and 6 weeks followed by 5 mg/kg q8 weeks.
• Patient who respond but show tolerance, increase dose to 10 mg/kg.
• In the absence of therapeutic effects treatment is discontinued by 14 weeks.